ProfileGDS5678 / 1425494_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 68% 68% 68% 67% 68% 68% 67% 71% 75% 68% 66% 67% 68% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.1736468
GSM967853U87-EV human glioblastoma xenograft - Control 24.140668
GSM967854U87-EV human glioblastoma xenograft - Control 34.1446368
GSM967855U87-EV human glioblastoma xenograft - Control 44.1444467
GSM967856U87-EV human glioblastoma xenograft - Control 54.0981968
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.1722568
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.1406267
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.420971
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.9350575
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1306368
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.9894366
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.1041567
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1280368
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1309268